Etanercept biosimilar - Daewoong Pharmaceutical

Drug Profile

Etanercept biosimilar - Daewoong Pharmaceutical

Alternative Names: DWP 422

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Daewoong Pharmaceutical
  • Class Antirheumatics; Disease-modifying antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Rheumatoid arthritis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in South Korea (Parenteral, Injection)
  • 23 Jul 2012 Daewoong Pharmaceutical plans a phase I trial of DWP 422 in healthy volunteers in South Korea (NCT01635686)
  • 23 May 2011 Etanercept biosimilar (DWP 422) licensed to Bi-nex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top